-
All about
#CureTech. Tagged on http://bit.ly/VxjAVc -
Medivation buys into PD-1, picking up where Teva left off http://bit.ly/1CvrYZ7
#CureTech -
Despite all its efforts,
#CureTech did not manage to secure new investors to fund its operations https://www.calcalistech.com/ctech/articles/0,7340,L-3787658,00.html … -
Teva and CureTech Announce Positive Phase II Data from CT-011
#Teva#CureTech#CT011#monoclonalantibody#lymp... http://tinyurl.com/64wluav -
#Teva terminates#collaboration with#CureTech: http://bit.ly/VxjDjU |#termination#Industries -
#Medivation has signed a exclusive#pharma#licensing deal with#CureTech | http://bit.ly/1FSIeU9 -
#USAN#cancer drug#name#PIDILIZUMAB (CT-011)#Antineoplastic (anti-#PD-1#monoclonal#antibody)#CureTech (followed by#InTextoResearch -
#Teva Continues to Narrow its Focus: Ends Collaboration on#CureTech’s#Cancer Medicine http://bloom.bg/XUImJM via @BloombergNews -
#Teva Announces Termination of Agreements with#CureTech http://bit.ly/12c9f2S -
...and as quickly as they came, they were gone.
#curetech#cureHQmove @ CURE International https://www.instagram.com/p/BIFimzNDvr1/ -
A new
#ExpertReview published today of#CureTech's and#TevaPharmaceutical's anti-programmed death-1 receptor mAb#CT011 for#cancer
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.